The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply. Eli Lilly, the maker of Zepbound and Mounjaro, and Novo ...
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback